Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19.
Taiwo BO, Chew KW, Moser C, Wohl DA, Daar ES, Li JZ, Greninger AL, Bausch C, Luke T, Hoover K, Neytman G, Giganti MJ, Olefsky M, Javan AC, Fletcher CV, Eron JJ, Currier JS, Hughes MD, Smith DM; ACTIV-2/A5401 Study Team. Taiwo BO, et al. Among authors: olefsky m. J Infect Dis. 2023 Jul 14;228(2):133-142. doi: 10.1093/infdis/jiad013. J Infect Dis. 2023. PMID: 36661240 Free PMC article. Clinical Trial.
Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353.
Nyaku AN, Zheng L, Gulick RM, Olefsky M, Berzins B, Wallis CL, Godfrey C, Sax PE, Acosta EP, Haas DW, Smith KY, Sha BE, Van Dam CN, Taiwo BO; ACTG A5353 Study Team. Nyaku AN, et al. Among authors: olefsky m. J Antimicrob Chemother. 2019 May 1;74(5):1376-1380. doi: 10.1093/jac/dky564. J Antimicrob Chemother. 2019. PMID: 30668695 Free PMC article. Clinical Trial.
Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy.
Taiwo BO, Quiñones-Mateu ME, Smith K, Zheng L, Gulick R, Nyaku AN, Sax PE, Ha B, Kumwenda J, Olefsky M, Godfrey C, Wallis C. Taiwo BO, et al. Among authors: olefsky m. AIDS Res Hum Retroviruses. 2020 Apr;36(4):254-255. doi: 10.1089/AID.2019.0253. Epub 2020 Mar 9. AIDS Res Hum Retroviruses. 2020. PMID: 31914799 Free PMC article. No abstract available.
Antiretroviral Therapy Initiation Is Associated With Decreased Visceral and Subcutaneous Adipose Tissue Density in People Living With Human Immunodeficiency Virus.
Debroy P, Lake JE, Moser C, Olefsky M, Erlandson KM, Scherzinger A, Stein JH, Currier JS, Brown TT, McComsey GA. Debroy P, et al. Among authors: olefsky m. Clin Infect Dis. 2021 Mar 15;72(6):979-986. doi: 10.1093/cid/ciaa196. Clin Infect Dis. 2021. PMID: 32107532 Free PMC article. Clinical Trial.
The immunogenicity of an HIV-1 Gag conserved element DNA vaccine in people with HIV and receiving antiretroviral therapy.
Jacobson JM, Felber BK, Chen H, Pavlakis GN, Mullins JI, De Rosa SC, Kuritzkes DR, Tomaras GD, Kinslow J, Bao Y, Olefsky M, Rosati M, Bear J, Heptinstall JR, Zhang L, Sawant S, Hannaman D, Laird GM, Cyktor JC, Heath SL, Collier AC, Koletar SL, Taiwo BO, Tebas P, Wohl DA, Belaunzaran-Zamudio PF, McElrath MJ, Landay AL; ACTG 5369 Study Team. Jacobson JM, et al. Among authors: olefsky m. AIDS. 2024 Jun 1;38(7):963-973. doi: 10.1097/QAD.0000000000003804. Epub 2023 Dec 1. AIDS. 2024. PMID: 38051788 Clinical Trial.
Pharmacokinetics of dose-adjusted levonorgestrel emergency contraception combined with efavirenz-based antiretroviral therapy or rifampicin-containing tuberculosis regimens.
Scarsi KK, Smeaton LM, Podany AT, Olefsky M, Woolley E, Barr E, Pham M, Mawlana S, Supparatpinyo K, Gatechompol S, Jalil EM, Gadama L, Badal-Faesen S, Belaunzaran-Zamudio PF, Godfrey C, Cohn SE, Mngqibisa R; AIDS Clinical Trials Group A5375 Study Team. Scarsi KK, et al. Among authors: olefsky m. Contraception. 2023 May;121:109951. doi: 10.1016/j.contraception.2023.109951. Epub 2023 Jan 12. Contraception. 2023. PMID: 36641094 Free PMC article. Clinical Trial.
Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis.
Agyemang N, Scarsi KK, Baker P, Smeaton LM, Podany AT, Olefsky M, Woolley E, Barr E, Pham M, Mawlana S, Supparatpinyo K, Gatechompol S, Jalil EM, Gadama L, Badal-Faesen S, Van Schalkwyk M, Kayama C, Belaunzaran-Zamudio PF, Godfrey C, Cohn SE, Mngqibisa R, Haas DW; AIDS Clinical Trials Group A5375 Study Team. Agyemang N, et al. Among authors: olefsky m. Pharmacogenet Genomics. 2023 Aug 1;33(6):126-135. doi: 10.1097/FPC.0000000000000501. Epub 2023 Jun 12. Pharmacogenet Genomics. 2023. PMID: 37306344 Free PMC article.